PCN5 PHARMACOECONOMIC ANALYSIS OF SORAFENIB AND SUNITINIB FOR FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) COMPARED WITH COMBINATION THERAPY OF BEVACIZUMAB, GEMCITABINE, AND CAPECITABINE (BGC) AT A LARGE CANCER CENTER
May 1, 2007, 00:00
10.1016/S1098-3015(10)68916-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)68916-4/fulltext
Title :
PCN5 PHARMACOECONOMIC ANALYSIS OF SORAFENIB AND SUNITINIB FOR FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) COMPARED WITH COMBINATION THERAPY OF BEVACIZUMAB, GEMCITABINE, AND CAPECITABINE (BGC) AT A LARGE CANCER CENTER
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)68916-4&doi=10.1016/S1098-3015(10)68916-4
First page :
Section Title :
Open access? :
No
Section Order :
94